Inside Precision Medicine March 18, 2025
Malorye Branca

It’s been a very active period for European venture capital firm Sofinnova Partners. The firm announced the final close of its latest investment fund as well as the launch of three new companies. The Biovelocita II accelerator fund raised €165 million ($181 million)—exceeding its target. Notably, the fund has backing from drugmakers including Amgen, Bristol Myers Squibb, and Pfizer Ventures.

The three start-ups are:

Italian fiBioClec—headquartered in Italy—is focused on developing disease-modifying interventions that target a novel microglial pathway in Alzheimer’s disease. Marco Colonna, co-founder of the company, which is still in its discovery phase, said that “by targeting [microglia], we aim to revolutionize the treatment of Alzheimer’s disease.”

Forth Therapeutics, a spin-out of the University of Edinburgh, is...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, Investments, Pharma / Biotech, Trends
Related Articles:
Pharma Dodges The Tariff Bullet — But For How Long?
Noom, LillyDirect pharmacy provider partner to increase access to Zepbound
PBM Private Labeling Boosts Biosimilars, Raises Concerns
Q&A: How can drug repurposing lower drug costs and improve care?
BC researchers receive $49M for genomics projects

Share This Article